Health Care [ 12/12 ] | Pharmaceuticals [ 64/74 ]
NASDAQ | Common Stock
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders.
The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders.
In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers.
Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 24 | -0.97 Decreased by -64.41% | -1.14 Increased by +14.91% |
| May 15, 24 | -0.63 Decreased by -16.67% | -0.58 Decreased by -8.62% |
| Mar 26, 24 | -0.15 Decreased by -107.32% | -0.55 Increased by +72.73% |
| Nov 9, 23 | -0.60 Decreased by -114.29% | -0.62 Increased by +3.23% |
| Aug 9, 23 | -0.59 Decreased by -20.41% | -0.57 Decreased by -3.51% |
| May 9, 23 | -0.54 Decreased by -1.89% | -0.56 Increased by +3.57% |
| Mar 13, 23 | 2.05 Increased by +654.05% | -0.57 Increased by +459.65% |
| Nov 9, 22 | -0.28 Increased by +22.22% | -0.56 Increased by +50.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Decreased by N/A% | -32.23 M Increased by +13.57% | - - |
| Jun 30, 24 | 0.00 Decreased by N/A% | -56.04 M Decreased by -66.29% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 1.37 M Increased by +N/A% | -37.18 M Decreased by -128.88% | Decreased by -2.72 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -37.75 M Decreased by -213.33% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -37.29 M Decreased by -666.00% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -33.70 M Increased by +10.03% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Increased by +100.00% | 128.73 M Decreased by -54.13% | Increased by +N/A% Increased by +N/A% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | 33.31 M Increased by +246.72% | Increased by +N/A% Increased by +N/A% |